3124-87-6Relevant academic research and scientific papers
Novel rimantadine analog and synthetic method thereof
-
Paragraph 0033; 0035; 0053; 0054; 0059; 0060, (2019/04/17)
The invention provides a novel rimantadine analog. The novel rimantadine analog has a structure shown in formula (I). The rimantadine analog has high activity and is more beneficial to clinical use and further development and research of drugs.
Aniline-Based Inhibitors of Influenza H1N1 Virus Acting on Hemagglutinin-Mediated Fusion
Leiva, Rosana,Barniol-Xicota, Marta,Codony, Sandra,Ginex, Tiziana,Vanderlinden, Evelien,Montes, Marta,Caffrey, Michael,Luque, F. Javier,Naesens, Lieve,Vázquez, Santiago
supporting information, p. 98 - 118 (2018/02/10)
Two series of easily accessible anilines were identified as inhibitors of influenza A virus subtype H1N1, and extensive chemical synthesis and analysis of the structure-activity relationship were performed. The compounds were shown to interfere with low pH-induced membrane fusion mediated by the H1 and H5 (group 1) hemagglutinin (HA) subtypes. A combination of virus resistance, HA interaction, and molecular dynamics simulation studies elucidated the binding site of these aniline-based influenza fusion inhibitors, which significantly overlaps with the pocket occupied by some H3 HA-specific inhibitors, indicating the high relevance of this cavity for drug design.
Methods for Modulating Bacterial Virulence and Related Compounds
-
Paragraph 0225, (2014/09/30)
The present invention relates to compounds and methods for the treatment of bacterial infections. The compounds and methods involve the disruption of the QseC signaling pathway which modulates the virulence of some bacteria. This methodology for treatment
